Verve Therapeutics, Inc. (VERV)
Jul 25, 2025 - VERV was delisted (reason: acquired by LLY)
11.13
0.00 (0.00%)
Inactive · Last trade price on Jul 24, 2025
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Verve Therapeutics stock had an average target of 14.57, with a low estimate of 11 and a high estimate of 24.
Price Target: $14.57 (+30.91%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 27, 2025.
Analyst Ratings
The average analyst rating for Verve Therapeutics stock from 11 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 2 | 2 |
| Buy | 1 | 1 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 7 | 7 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy → Hold Downgrades $20 → $14 | Buy → Hold | Downgrades | $20 → $14 | +21.29% | Jun 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $14 | Strong Buy → Hold | Downgrades | $14 | +21.29% | Jun 18, 2025 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades $12 | Buy → Hold | Downgrades | $12 | +7.82% | Jun 18, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $28 → $11 | Strong Buy → Hold | Downgrades | $28 → $11 | -1.17% | Jun 18, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 17, 2025 |
Financial Forecast
Revenue This Year
47.63M
from 32.33M
Increased by 47.32%
Revenue Next Year
23.36M
from 47.63M
Decreased by -50.95%
EPS This Year
-2.54
from -2.35
EPS Next Year
-3.00
from -2.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 75.8M | 54.9M | 52.5M | ||
| Avg | 47.6M | 23.4M | 22.4M | ||
| Low | 32.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 134.5% | 15.3% | 124.7% | ||
| Avg | 47.3% | -51.0% | -4.0% | ||
| Low | -0.0% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.27 | -2.72 | -2.42 | ||
| Avg | -2.54 | -3.00 | -2.77 | ||
| Low | -2.92 | -3.73 | -3.29 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.